載入中
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
一般交易時段
US$0.2749
−US$0.0051 · -1.82%
盤中時間採用ET。市場資料可能有所延遲。
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
日內區間
目前US$0.2749
52週區間
目前US$0.2749
盤中時間採用ET。市場資料可能有所延遲。
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
日內區間
目前US$0.2749
52週區間
目前US$0.2749
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$18.25
上漲空間 6538.78%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年5月11日 | 1:50 | — | — |
股票分割 | 2022年10月21日 | 1:50 | — | — |
股票分割 | 2022年8月26日 | 2:1 | — | — |
已生效 2026年5月11日
1:50
已生效 2022年10月21日
1:50
已生效 2022年8月26日
2:1
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
